Company Overview
Xenetic Biosciences, Inc. is a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers. The Company's DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in cancer progression. Xenetic is currently focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and locally advanced or metastatic solid tumors.
Recent News
Xenetic Biosciences, Inc. Announces Executive Leadership Transition
Xenetic Biosciences, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update
Stock Overview
07/26/2024 03:30 PM EDT
Investor Relations
JTC Team, LLC.
Jenene Thomas
T: 833-475-8247
xbio@jtcir.com